179057-22-8

Basic information

• Product Name: Benzenesulfonamide, 4-formyl-N-phenyl-
• CAS NO: 179057-22-8
• Molecular Formula: C13H11NO3S
• Molecular Weight: 261.301
• Mol File: 179057-22-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, 4-formyl-N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, 4-formyl-N-phenyl-(179057-22-8)
• EPA Substance Registry System: Benzenesulfonamide, 4-formyl-N-phenyl-(179057-22-8)

Safety Data

• Hazardous Substances Data: 179057-22-8(Hazardous Substances Data)

Upstream product

• 69812-51-7 4-chlorosulfonyl-benzoic acid methyl ester 
• 98-59-9 p-toluenesulfonyl chloride 
• 69232-47-9 (4-(chlorosulfonyl)phenyl)methylene diacetate 
• 114958-19-9 4-Phenylsulfamoyl-benzoyl chloride 
• 62-53-3 aniline 
• 6314-72-3 4-(N-phenyl)sulfamoylbenzoic acid 
• 10130-89-9 p-carboxyphenylsulfonyl chloride 
• 85822-16-8 4-formylbenzene-1-sulfonyl chloride 
• 179055-19-7 N-methoxy-N-methyl-4-(phenylsulfamoyl)benzamide 
• 857005-28-8 4-diacetoxymethyl-benzenesulfonic acid anilide 

Downstream Products

• 179055-53-9 4-cycloheptylaminomethyl-N-phenyl-benzenesulfonamide 

Relevant articles and documents

Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation

The first allosteric, type III inhibitor of LIM-kinase 2 (LIMK2) is reported. A series of molecules that feature both an N-phenylsulfonamide and tertiary amide were not only very potent at LIMK2 but also were extremely selective against a panel of other k

Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer

Nicotinamide phosphoribosyltransferase (NAMPT) has emerged as a promising target for the discovery of anticancer drugs. Based on NAMPT inhibitor FK866 that has been advanced into phase II trial, we identified a trans-3-(pyridin-3-yl)acrylamide compound 13 incorporating with a biarylsulfanilamide moiety as a new NAMPT inhibitor. Further structure-activity relationship (SAR) exploration led to additional biarylsulfanilamide-derived compounds with high in vitro NAMPT inhibitory potency and antiproliferative activity. In particular, compound 23, the most potent NAMPT inhibitor (IC50 = 5.08 nM), showed single-digit nanomolar antiproliferative activity against DU145, Hela, and H1975 cells with IC50 values of 2.90 nM, 2.34 nM, and 2.24 nM, respectively, and even subnanomolar level against K562, MCF-7, and HUH7 cells with IC50 values of 0.46 nM, 0.23 nM and 0.53 nM, respectively. Our findings provided promising lead compounds for the discovery of more potent NAMPT inhibitors as anticancer drugs.

Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles

The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenz-imidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependency protects human CD4 + and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.